Evaluation of the effectiveness and the possibility of optimizing the methodology for analyzing the plasma microRNA-371-3 (HSA-miR-371-3p) level for the diagnosis and monitoring of the effect of therapy of germ cell tumors in men
- 作者: Knyazeva M.S1,2, Zagoruyko V.A1,2, Borisov E.V1,2, Sidina E.I1,2, Nikiforova N.S1,2, Slyusarenko M.A1,2, Nazarova I.V1,2, Semenova A.I1,2, Nosov A.K1,2, Protsenko S.A1,2, Malek A.V1,2
-
隶属关系:
- N.N. Petrov National Medical Research Center of Oncology
- Onco-System
- 期: 卷 27, 编号 7 (2020)
- 页面: 68-75
- 栏目: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312724
- DOI: https://doi.org/10.18565/pharmateca.2020.7.68-75
- ID: 312724
如何引用文章
详细
全文:
作者简介
M. Knyazeva
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
V. Zagoruyko
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
E. Borisov
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
E. Sidina
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
N. Nikiforova
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
M. Slyusarenko
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
I. Nazarova
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
A. Semenova
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
A. Nosov
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
S. Protsenko
N.N. Petrov National Medical Research Center of Oncology; Onco-SystemSt. Petersburg, Russia; Moscow, Russia
A. Malek
N.N. Petrov National Medical Research Center of Oncology; Onco-System
Email: anastasia@malek.com
Cand. Sci. (Med.), Head of the Laboratory of Subcellular Technologies St. Petersburg, Russia; Moscow, Russia
参考
- Rajpert-De Meyts E, McGlynn K.A., Okamoto K, et al. Testicular germ cell tumours. Lancet. 2016;387(10029):1762-74. Doi: 10.1016/ S0140-6736(15)00991-5
- Einhorn L.H. Treatment of testicular cancer: A new and improved model. J Clin Oncol. 1990;8:1777-81. doi: 10.1200/JCO.1990.8.11.1777.
- Honecker F, Aparicio J., Berney D, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29(8):1658-86. Doi: 10.1093/ annonc/mdy217.
- Batool A., Karimi N., Wu X.N., et al. Testicular germ cell tumor: a comprehensive review. Cell Mol Life Sci. 2019;76(9):1713-27. Doi: 10.1007/ S00018-019-03022-7.
- Трякин А.А, Гладков О.А., Матвеев В.Б. и др. Практические рекомендации по лекарственному лечению герминогенных опухолей у мужчин. Практические рекомендации RUSSCO. 2016.
- Leao R, Ahmad A.E., Hamilton R.J. Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer. Clin Genitourin Cancer 2019;17(1):e176-83. Doi: 10.1016/]. clgc.2018.10.007.
- Narita T, Hatakeyama S., Yoneyama T, et al. Clinical implications of serum N- glycan profiling as a diagnostic and prognostic biomarker in germ-cell tumors. Cancer Med. 2017;6(4):739-48. doi: 10.1002/cam4.1035.
- Ellinger J, Wittkamp V., Albers P, et al. Cell-Free Circulating DNA: Diagnostic Value in Patients With Testicular Germ Cell Cancer. J Urol. 2009;181:363-371. doi: 10.1016/j.juro.2008.08.118.
- Cebotaru C.L., Olteanu E.D., Antone N.Z., et al. Circulating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A review. Med Pharm Reports. 2016;89(2):203-11. doi: 10.15386/cjmed-570.
- Tafrihi M., Hasheminasab E. MiRNAs: Biology, Biogenesis, their Web-based Tools, and Databases. MicroRNA. 2018. doi: 10.2174/221153660766 6180827111633.
- Wang J., Chen J., Sen S. MicroRNA as Biomarkers and Diagnostics. J Cell Physiol. 2016;231(1):25-30. doi: 10.1002/jcp.25056.
- Max K.E.A., Bertram K., Akat K.M., et al. Human plasma and serum extracellular small RNA reference profiles and their clinical utility. Proc. Natl. Acad. Sci. 2018;115(23):E5334-43. doi: 10.1073/pnas.1714397115.
- Izzotti A., Carozzo S., Pulliero A., et al. Extracellular MicroRNA in liquid biopsy: applicability in cancer diagnosis and prevention. Am J Cancer Res. 2016;6(7):1461-93.
- Toiyama Y, Okugawa Y, Fleshman J., et al. MicroRNAs as potential liquid biopsy biomarkers in colorectal cancer: A systematic review. Biochim Biophys. Acta - Rev Cancer. 2018;1870(2):274-82. doi: 10.1016/j.bbcan.2018.05.006.
- Kashyap D., Kaur H. Cell-free miRNAs as noninvasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction. Life Sci. 2020;246:117417. Doi: 10.1016/j. lfs.2020.117417.
- Jiang M., Li X., Quan X., et al. Clinically Correlated MicroRNAs in the Diagnosis of Non-Small Cell Lung Cancer: A Systematic Review and MetaAnalysis. Biomed Res Int. 2018;2018:1-14. doi: 10.1155/2018/5930951.
- Git A., Dvinge H., Salmon-Divon M., et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16(5):991-1006. doi: 10.1261/rna.1947110.
- Faraldi M., Gomarasca M., Banfi G., Lombardi G. Free Circulating miRNAs Measurement in Clinical Settings: The Still Unsolved Issue of the Normalization. Adv Clin Chem. 2018;87:113-39. doi: 10.1016/bs.acc.2018.07.003.
- Palmer R.D., Murray M.J., Saini H.K., et al. Malignant Germ Cell Tumors Display Common MicroRNA Profiles Resulting in Global Changes in Expression of Messenger RNA Targets. Cancer Res. 2010;70(7):2911-23. doi: 10.1158/0008-5472.CAN-09-3301.
- Dieckmann K.-P, Spiekermann M., Balks T, et al. MicroRNAs miR-371-3 in serum as diagnostic tools in the management of testicular germ cell tumours. Br J Cancer. 2012;107(10):1754-60. doi: 10.1038/bjc.2012.469.
- Myklebust M.P, Rosenlund B., Gjengsts P, et al. Quantitative PCR Measurement of miR-371a-3p and miR-372-p Is Influenced by Hemolysis. Front Genet. 2019;22;10:463. Doi: 10.3389/ fgene.2019.00463.
- Spiekermann M., Dieckmann K.-P, Balks T., Bullerdiek J., Belge G. Is relative quantification dispensable for the measurement of microRNAs as serum biomarkers in germ cell tumors? Anticancer Res. 2015;35(1):117-21.
- Dieckmann K.-P, Radtke A., Geczi L., et al. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. J Clin Oncol. 2019;37(16):1412-23. Doi: 10.1200/ JCO.18.01480.
- Benes V., Castoldi M. Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods. 2010;50:244-49 Doi: 10.1016/j. ymeth.2010.01.026.
- Androvic P, Valihrach L., Elling J., et al. Twotailed RT-qPCR: A novel method for highly accurate miRNA quantification. Nucleic Acids Res. 2017;45(15):1-13. doi: 10.1093/nar/gkx588.
- Korobkina E.A., Knyazeva M.S.P, Kil Y.V., et al. Comparative analysis of rt-qpcr based methodologies for m1crorna detection. Klin Lab Diagnostika. 2018;63(11):722-28. doi: 10.18821/0869- 2084-2018-63-11-722-728.